Combination Products

Feedback on Combination Products

The Office of Combination Products (OCP) strives to ensure efficient, effective and clear premarket and postmarket policies and practices related to combination products and to the classification and assignment of human medical products. OCP welcomes comments from interested stakeholders on any policy issues that you believe should be addressed or clarified in guidance, regulations or otherwise. OCP also encourages medical product developers to contact us if they are uncertain about the classification or assignment of their products and with questions regarding premarket or postmarket considerations for combination products.

Please direct any comments or questions to

Contact FDA

Office of Combination Products

Food and Drug Administration

WO32, Hub/Mail Room #5129

10903 New Hampshire Avenue

Silver Spring, MD 20993

Page Last Updated: 03/19/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English